Pfizer ordered to withdraw journal ad

Share this article:
A UK government agency told Pfizer to take down an ad for Zyvox due to potentially misleading claims about the antibiotic. The ads had run in the British Medical Journal and claimed that Zyvox (linezolid) has “superior cure rates” compared to products containing the active ingredient vancomycin, according to the UK-based Medicines and Healthcare products Regulatory Agency (MHRA). Pfizer suspended all advertising containing the claim, MHRA said, although the agency advised the firm to continually review its advertising to ensure the right balance of risks and benefits is presented and to take appropriate action if new safety data becomes available. Pfizer wrote to healthcare professionals this week to inform them about new safety restrictions on the use of Zyvox.
Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.